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Abstract 
X-linked thrombocytopenia (XLT) is a rare bleeding 
disorder characterized by isolated thrombocytopenia 
with small-sized platelets. XLT is a milder clinical 
variant of Wiskott-Aldrich syndrome (WAS), which 
is characterized by the clinical triad of eczema, 
susceptibility to infection and thrombocytopenia, 
while patients with XLT only present with 
thrombocytopenia. XLT is caused by a mutation in 
the WAS gene. 
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Identity 
Inheritance 
X-linked recessive with estimated incidence 
between 1 and 10 per million males worldwide. This 
condition is rarer among females. 
Clinics 
Phenotype and clinics 
The disease presents as a bleeding disorder with easy 
bruising, mucosal bleeding, such as nosebleeds, and 
mild to severe anemia. It is less common to have 
eczema or immunological disturbances as compared 
to WAS.  
Thrombocytopenia associated with small platelet 
volume is a consistent finding. In most patients the 
mean platelet volume is half that of normal control 
subjects.  
Life-threatening bleeding, including severe oral 
bleeding, gastrointestinal bleeding, and intracranial 
hemorrhage, has been reported.  
Autoimmune diseases are rare, but have also been 
reported to occur.  
Additionally, there is a milder form of the disorder 
called intermittent thrombocytopenia where patients 
have normal platelet production with intermittent 
episodes of thrombocytopenia. 
Differential Diagnosis 
Wiskott-Aldrich syndrome:   X-linked 
thrombocytopenia (XLT) is recognized as a variant 
of WAS. Both are caused by mutations in WAS. 
Males suffering from WAS or XLT have a 
congenital thrombocytopenia from moderate to very 
severe with small platelets. However, patients with 
WAS also have a severe immune dysregulation with 
susceptibility to infections, eczema, or autoimmune 
phenomena, and are at risk of lymphoproliferative 
disorders. If the WAS protein is truncated or not 
expressed, patients are likely to suffer from the 
severe WAS phenotype. Instead, XLT is typically 
associated with missense mutations and patients 
often show expression, even at reduced levels, of 
normal-sized WAS protein (Balduini 2012).  
GATA1-related thrombocytopenias:  Germline 
mutations in the X-linked GATA1 cause two rare 
GATA1-related thrombocytopenias: 
dyserythropoietic anemia with thrombocytopenia 
and X-linked thrombocytopenia with beta-
thalassemia (XLTT). In contrast to XLT, both are 
characterized by dyserythropoiesis and 
dysmegakaryopoiesis with variable degrees of 
anemia and macrothrombocytopenia (large platelets) 
whereas in XLT, platelets are small. Moreover, in 
XLTT, there is an unbalanced α:β globin chain 
synthesis manifesting as mild β-thalassemia 
(Balduini 2012). Thus, GATA1-related 
thrombocytopenias should be suspected in males 
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with congenital thrombocytopenia, abnormal red cell 
morphology and a hypercellular bone marrow. 
Neoplastic risk 
In one study, malignancy developed at a median age 
of 34 years, half of which were hematolymphoid in 
origin (Albert et al. 2010). Overall, the incidence of 
malignancies in patients of the XLT phenotype is 
increased, but lower than that in classic WAS. 
Treatment 
Treatment options are controversial. XLT is 
typically treated conservatively and do not require 
standard prophylactic interventions. Patients with 
declining immune function may benefit from IVIG. 
Allogeneic hematopoietic stem cell transplantation 
(HSCT) may be considered on a case by case basis 
(Albert et al. 2010). 
Prognosis 
XLT patients generally have a benign disease course 
and excellent long-term survival, and life expectancy 
is not as significantly affected. However, severe 
disease-related events such as infections, bleeding, 
autoimmune diseases, and malignancies can result 
(Albert et al. 2010). 
Genes involved and 
proteins 
WAS 
Alias 
IMD2, THC, thrombocytopenia 1 (X-linked), 
Wiskott-Aldrich syndrome (eczema-
thrombocytopenia), WASP, WASPA, SCNX, THC1 
Location Xp11.23 
Mutations of the WAS gene result in three distinct 
phenotypes: Wiskott-Aldrich Syndrome (WAS), X-
linked thrombocytopenia (XLT), and X-linked 
neutropenia (XLN). 
DNA/RNA 
Description 
1823 bp; 12 exons 
Protein 
Description 
502 amino acids; 54 kDa; consists of an N-terminal 
Ena-VASP homology domain 1 (EVH1), a basic 
domain, a GTPase binding domain (GBD), 
polyproline domain and the C-terminal domain 
comprising of a cluster of verprolin homology (V), 
central (C) and acidic regions (A) (the VCA 
domain). 
Expression 
Consitutively expressed in all haematopoietic stem-
cell-derived lineages, except in mature red blood 
cells. WASL (Neural WASP, N-WASP) and WASP 
family verprolin homologous protein 1 WASF1, 
WASF2 and WASF3 (WAVE1, WAVE2 and 
WAVE3) are more widely expressed. 
Localisation 
Located in the cytoplasmic compartment with 
highest density along the cell membrane. 
Function 
WAS protein acts as an adaptor to bring together 
downstream mediators that facilitate ACTR2/ 
ACTR3 (Arp2/3)-mediated actin polymerization. A 
lack of WAS results in cytoskeletal defects that 
compromise multiple aspects of normal cellular 
activity including proliferation, phagocytosis, 
immune synapse formation, adhesion and directed 
migration. 
Mutations 
Note 
The XLT phenotype is generally those with missense 
or splice-site mutations that allow expression of 
normal-sized mutated protein, often in reduced 
quantity. Three of the six hotspot mutations 
(168C>T; 290 C>N/291 G>N and IVS6+5g>a) have 
been found consistently in WASP-positive patients.  
In one study that evaluated 81 affected members 
form 75 unrelated families, all of the patients with 
XLT (except one) had missense mutations with 75% 
having detectable WASp in the peripheral blood, and 
the majority of patients with classic WAS had null 
mutations or splice site mutations without expression 
of WASp. These findings suggest there is a potential 
association of genotype and phenotype (Liu 2015). 
Thus, perhaps the clinical phenotype and long-term 
outcome of patients with WAS are potentially 
influenced by the effect of these WAS mutations. 
Patients with missense mutations that allow 
expression of mutated WASp and those with splice 
anomalies, which result in generation of multiple 
products, including normal WASp, present with the 
attenuated XLT phenotype and show better 
prognosis (Liu 2015). 
Germinal 
More than 295 unique mutations have been 
identified.  
158 unique WASP gene mutations had been 
identified in a cohort of 270 unrelated WAS/XLT 
families. The most common are missense mutations, 
followed by splice-site mutations, short deletions, 
and nonsense mutations. Insertions, complex 
mutations, and large deletions are less frequent. 
Most deletions and insertions involve fewer than 10 
nucleotides and result in frame shifting and early 
termination of transcription.  
Amino acid substitutions are typically located in 
exons 1-4. Splice-site mutations occur 
predominantly in the downstream half of the WASP 
gene (introns 6-12).  
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Mutations affecting invariant splice sites may result 
in multiple splicing products, which often include 
small amounts of normal WASP cDNA.  
Six mutational hotspots, defined as occurring in > 
2,5% of the population, have been identified. Three 
of these hotspots represent point mutations within 
the coding regions, whereas the other three involve 
splice sites. 
Somatic 
Patients with WAS and XLT have variable clinical 
findings even within families. This variability could 
be also associated with somatic mutations that are 
commonly detected in lymphocytes of WAS 
patients. Many of these somatic events restore the 
expression of WASp conferring a selective 
proliferation and differentiation advantage to 
affected cells. However, it still unknown whether 
revertant clones are associated with clinical 
improvement (Balduini 2012). 
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